Chemistry - Nicotine dosage
Cannabis-derived medical products face rigorous regulatory scrutiny requiring comprehensive purity assessment - unexpected nicotine contamination from tobacco exposure or processing compromises product quality and regulatory compliance. Nicotine quantification in CBD products ensures compliance with Swissmedic directives for cannabis-containing medical products, with GC-MS methodology providing specific identification and quantification in complex botanical matrices. Essential for quality control of CBD medical products demonstrating pharmaceutical-grade purity, demonstrating absence of nicotine contamination from co-cultivation with tobacco or processing equipment cross-contamination, and supporting regulatory submissions for cannabis-based therapeutics requiring comprehensive purity profiles. The GC-MS approach distinguishes nicotine from structural analogs and other alkaloids ensuring measurement specificity, while providing quantification below regulatory thresholds protecting patients from unexpected nicotine exposure. For medical cannabis products, nicotine contamination indicates cultivation problems where tobacco and cannabis grow in proximity, processing contamination where equipment handles both plant types, or raw material adulteration compromising product integrity. The testing supports pharmaceutical cannabis development ensuring botanical starting materials meet purity requirements, manufacturing validation confirming processing doesn't introduce nicotine contamination, and quality control releasing products meeting regulatory specifications. Swiss regulatory requirements for medical cannabis products demand documented nicotine testing supporting product authorization and ongoing batch release, making this analysis essential for market access in regulated medical cannabis markets.